GlassScriptPhysician profile
Laurel Beth Holze
NPI 1700924040
$1,307.87
in general payments reported to CMS, 2019-2025
18 companies · $342 in 2025
The $342 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $111 · 2022: $251 · 2023: $290 · 2024: $313 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $945.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $326.89 | 2021-2025 | |
| Alkermes, INC. | $212.91 | 2021-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $93.67 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $93.40 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $88.57 | 2023-2025 | Zepbound |
| Corium, LLC | $72.88 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $64.19 | 2022-2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $51.52 | 2021-2025 | Spravato |
| Lundbeck LLC | $50.15 | 2021-2024 | Rexulti |
| Novo Nordisk INC | $49.73 | 2025 | Ozempic, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $38.89 | 2022-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $37.38 | 2024 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $36.66 | 2023-2024 | Quviviq |
| Vanda Pharmaceuticals INC. | $35.53 | 2022-2024 | Fanapt |
| Biogen, INC. | $15.00 | 2025 | Zurzuvae |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $14.48 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.72 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $12.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurel Holze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.